Abstract
Drug induced neutropenia as a consequence of intensive chemotherapy for hematological malignancies and solid tumors is known to be associated with severe, life-threatening infections such as neutropenic enterocolitis. However, the neutropenia associated with HCV combination therapy with Pegylated Interferon [PEG-IFN] and ribavirin is considered to be well tolerated in patients without other co-morbidities. We present a case of a severe gastrointestinal complication in a patient receiving HCV combination therapy and advocate caution in continuing therapy in patients with neutropenia, especially in the presence of underlying co-morbidities such as cirrhosis.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Antiviral Agents
-
Drug Therapy, Combination
-
Enterocolitis, Neutropenic / chemically induced*
-
Enterocolitis, Neutropenic / diagnosis
-
Enterocolitis, Neutropenic / drug therapy
-
Filgrastim
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
Hepatitis C / drug therapy
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / adverse effects*
-
Male
-
Middle Aged
-
Polyethylene Glycols / adverse effects*
-
Recombinant Proteins
-
Ribavirin / adverse effects*
-
Tomography, X-Ray Computed
Substances
-
Anti-Bacterial Agents
-
Antiviral Agents
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Granulocyte Colony-Stimulating Factor
-
Polyethylene Glycols
-
Ribavirin
-
Filgrastim
-
peginterferon alfa-2a